Logo image of ADAP

ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Stock Fundamental Analysis

USA - NASDAQ:ADAP - US00653A1079 - ADR

0.056 USD
+0.01 (+10.89%)
Last: 9/12/2025, 8:00:00 PM
0.061 USD
+0 (+8.93%)
After Hours: 9/12/2025, 8:00:00 PM
Fundamental Rating

2

Overall ADAP gets a fundamental rating of 2 out of 10. We evaluated ADAP against 541 industry peers in the Biotechnology industry. ADAP has a bad profitability rating. Also its financial health evaluation is rather negative. ADAP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADAP had negative earnings in the past year.
In the past year ADAP has reported a negative cash flow from operations.
ADAP had negative earnings in each of the past 5 years.
ADAP had negative operating cash flow in 4 of the past 5 years.
ADAP Yearly Net Income VS EBIT VS OCF VS FCFADAP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

ADAP's Return On Assets of -129.95% is on the low side compared to the rest of the industry. ADAP is outperformed by 82.62% of its industry peers.
Industry RankSector Rank
ROA -129.95%
ROE N/A
ROIC N/A
ROA(3y)-39.8%
ROA(5y)-36.38%
ROE(3y)-362.62%
ROE(5y)-240.54%
ROIC(3y)N/A
ROIC(5y)N/A
ADAP Yearly ROA, ROE, ROICADAP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

ADAP's Gross Margin of 273.43% is amongst the best of the industry. ADAP outperforms 99.63% of its industry peers.
ADAP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 273.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAP Yearly Profit, Operating, Gross MarginsADAP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

ADAP does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADAP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ADAP has been increased compared to 5 years ago.
ADAP has a worse debt/assets ratio than last year.
ADAP Yearly Shares OutstandingADAP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ADAP Yearly Total Debt VS Total AssetsADAP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -15.45, we must say that ADAP is in the distress zone and has some risk of bankruptcy.
ADAP's Altman-Z score of -15.45 is on the low side compared to the rest of the industry. ADAP is outperformed by 80.41% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.45
ROIC/WACCN/A
WACC9.12%
ADAP Yearly LT Debt VS Equity VS FCFADAP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ADAP has a Current Ratio of 1.52. This is a normal value and indicates that ADAP is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.52, ADAP is doing worse than 80.22% of the companies in the same industry.
ADAP has a Quick Ratio of 1.29. This is a normal value and indicates that ADAP is financially healthy and should not expect problems in meeting its short term obligations.
ADAP has a worse Quick ratio (1.29) than 82.44% of its industry peers.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.29
ADAP Yearly Current Assets VS Current LiabilitesADAP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ADAP have decreased strongly by -21.05% in the last year.
Looking at the last year, ADAP shows a very negative growth in Revenue. The Revenue has decreased by -53.99% in the last year.
Measured over the past years, ADAP shows a very strong growth in Revenue. The Revenue has been growing by 175.59% on average per year.
EPS 1Y (TTM)-21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
Revenue 1Y (TTM)-53.99%
Revenue growth 3Y207.05%
Revenue growth 5Y175.59%
Sales Q2Q%-89.33%

3.2 Future

Based on estimates for the next years, ADAP will show a very strong growth in Earnings Per Share. The EPS will grow by 38.30% on average per year.
ADAP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.60% yearly.
EPS Next Y-125.47%
EPS Next 2Y-17%
EPS Next 3Y-34.18%
EPS Next 5Y38.3%
Revenue Next Year-77.84%
Revenue Next 2Y-41.89%
Revenue Next 3Y-13.59%
Revenue Next 5Y12.6%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADAP Yearly Revenue VS EstimatesADAP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
ADAP Yearly EPS VS EstimatesADAP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADAP. In the last year negative earnings were reported.
Also next year ADAP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAP Price Earnings VS Forward Price EarningsADAP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAP Per share dataADAP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

ADAP's earnings are expected to decrease with -34.18% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17%
EPS Next 3Y-34.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADAP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAPTIMMUNE THERAPEUTICS-ADR

NASDAQ:ADAP (9/12/2025, 8:00:00 PM)

After market: 0.061 +0 (+8.93%)

0.056

+0.01 (+10.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners44.2%
Inst Owner Change-0.48%
Ins Owners0.35%
Ins Owner Change-0.26%
Market Cap14.84M
Analysts46.67
Price Target0.28 (400%)
Short Float %25.23%
Short Ratio0.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.86%
Min EPS beat(2)-24.87%
Max EPS beat(2)80.59%
EPS beat(4)2
Avg EPS beat(4)18.25%
Min EPS beat(4)-75.07%
Max EPS beat(4)92.37%
EPS beat(8)3
Avg EPS beat(8)30.42%
EPS beat(12)6
Avg EPS beat(12)25.8%
EPS beat(16)6
Avg EPS beat(16)-0.97%
Revenue beat(2)2
Avg Revenue beat(2)24.66%
Min Revenue beat(2)15.67%
Max Revenue beat(2)33.64%
Revenue beat(4)3
Avg Revenue beat(4)66.46%
Min Revenue beat(4)-42.36%
Max Revenue beat(4)258.91%
Revenue beat(8)4
Avg Revenue beat(8)34.35%
Revenue beat(12)7
Avg Revenue beat(12)109.28%
Revenue beat(16)8
Avg Revenue beat(16)74.59%
PT rev (1m)-80.96%
PT rev (3m)-82.55%
EPS NQ rev (1m)-2.41%
EPS NQ rev (3m)33.59%
EPS NY rev (1m)8.6%
EPS NY rev (3m)-73.37%
Revenue NQ rev (1m)-48.84%
Revenue NQ rev (3m)-30.73%
Revenue NY rev (1m)-14.79%
Revenue NY rev (3m)-19.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.23
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.25
BVpS-0.27
TBVpS-0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -129.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 273.43%
FCFM N/A
ROA(3y)-39.8%
ROA(5y)-36.38%
ROE(3y)-362.62%
ROE(5y)-240.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.15%
Cap/Sales 4.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.52
Quick Ratio 1.29
Altman-Z -15.45
F-Score1
WACC9.12%
ROIC/WACCN/A
Cap/Depr(3y)187.66%
Cap/Depr(5y)146.98%
Cap/Sales(3y)39.72%
Cap/Sales(5y)67.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
EPS Next Y-125.47%
EPS Next 2Y-17%
EPS Next 3Y-34.18%
EPS Next 5Y38.3%
Revenue 1Y (TTM)-53.99%
Revenue growth 3Y207.05%
Revenue growth 5Y175.59%
Sales Q2Q%-89.33%
Revenue Next Year-77.84%
Revenue Next 2Y-41.89%
Revenue Next 3Y-13.59%
Revenue Next 5Y12.6%
EBIT growth 1Y-99.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-99.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.43%
OCF growth 3YN/A
OCF growth 5YN/A